BACKGROUND AND OBJECTIVES: The inactivation of the @entity5 suppressor gene @entity986 by methylation (p16M) has been recognized recently as an important process in the oncogenesis for a variety of @entity189 . There have been few reports of its use in @entity2 . We investigate p16M in @entity1 with @entity1149 ( @entity1149 ). METHODS: p16M in @entity5 , plasma, and pleural lavage fluid from @entity1 with resectable @entity1149 were investigated by using methylation-specific polymerase chain reaction. RESULTS: Of the 33 @entity1 studied, 14 (42%) had p16M @entity5 . There was a significant association between p16M @entity5 and advanced TNM staging (stage III or IV, P=0.047, Fisher exact test). Circulating p16M was identified in 2 of the 14 @entity1 with p16M @entity5 and was also associated with advanced TNM staging (P=0.049). The presence of plasma p16M in @entity1149 @entity1 and in p16M @entity5 @entity1 was associated with poor survival and shorter disease-free survival (P=0.0028, P=0.0039, Kaplan-Meier log rank). In addition, p16M was present in three preresectional and four postresectional lavage samples. Preresectional p16M was associated with poor survival and shorter disease-free survival (P=0.0085). p16M @entity5 involving the visceral pleura was significantly associated with positive p16M postresectional lavage. CONCLUSIONS: Positive @entity5 and plasma p16M indicate advanced staging in @entity1149 . @entity1 with plasma and preresection pleural lavage p16M have shorter survival. Further research in this direction is warranted.

Tumor p16M is a possible marker of advanced stage in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity986 :: ('1029', 'Gene') :: ['p16'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
